skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Overview
Datamonitor Healthcare uses a patient-based approach to size the commercial potential of Alzheimer’s disease across the US, Japan, and the five major EU markets (France, Germany, Italy, Spain, and the UK) from 2012 to 2021.

Highlights
Alzheimer’s disease across the US, Japan, and five major EU markets is set to double in value over the next 10 years. The catalysts for this growth include an increasingly elderly population, earlier and improved diagnosis, and the introduction of new therapeutic classes.

Pfizer/Eisai’s Aricept, formerly the highest selling brand in the market, has been overtaken by Forest/Lundbeck/Merz’s Namenda (memantine). The two drugs are following differing growth trajectories: Namenda’s sales will continue to rise while Aricept’s revenues are severely eroded by generic competition.

The beta amyloid immunotherapy solanezumab has the potential to grow the market by $4.6bn. Datamonitor Healthcare forecasts that around 330,000 patients with mild cognitive impairment or mild to moderate Alzheimer’s disease will receive immunotherapies annually by 2021 in the US, Japan, and the five major EU markets.

Methodology
Patient-based forecasting methodology utilizing epidemiology data and primary research with 133 neurologists across the US, Japan, and five major EU markets. Pricing, dosing, and future event assumptions are added to create Datamonitor Healthcare’s forecast.

 


This is an Alzheimer’s Disease analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: